KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
22
12
2023
accepted:
11
10
2024
revised:
04
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
Oncogenic mutations in KRAS are present in ~95% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic intraepithelial neoplasia (PanIN) precursor lesions. While it is well established that KRAS mutations drive the activation of oncogenic kinase cascades during pancreatic oncogenesis, the effects of oncogenic KRAS signaling on regulation of phosphatases during this process is not fully appreciated. Protein Phosphatase 2A (PP2A) has been implicated in suppressing KRAS-driven cellular transformation and low PP2A activity is observed in PDAC cells compared to non-transformed cells, suggesting that suppression of PP2A activity is an important step in the overall development of PDAC. In the current study, we demonstrate that KRAS
Identifiants
pubmed: 39443726
doi: 10.1038/s41388-024-03196-w
pii: 10.1038/s41388-024-03196-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pancreatic Cancer Action Network (Pancreatic Cancer Action Network, Inc.)
ID : 22-20-ALLE
Organisme : NCI NIH HHS
ID : U01 CA224012
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA186241
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287–92.
pubmed: 26985062
pmcid: 4869631
doi: 10.1242/jcs.182873
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91–100.
pubmed: 24388967
pmcid: 3955735
doi: 10.1016/j.tibs.2013.12.004
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450.
pubmed: 14706336
doi: 10.1016/S1535-6108(03)00309-X
Collins MA, Bednar F, Zhang Y, Brisset J-C, Galbán S, Galbán CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122:639–53.
pubmed: 22232209
pmcid: 3266788
doi: 10.1172/JCI59227
Storz P. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol. 2017;14:296–304.
doi: 10.1038/nrgastro.2017.12
Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Senescence in premalignant tumours. Nature. 2005;436:642.
pubmed: 16079833
doi: 10.1038/436642a
Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70:10474–84.
pubmed: 21159657
pmcid: 3056544
doi: 10.1158/0008-5472.CAN-10-2855
Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283:1004–24.
pubmed: 26507691
doi: 10.1111/febs.13573
Hydbring P, Larsson L-G. Cdk2: a key regulator of the senescence control function of Myc. Aging Albany 2010;2:244–50.
doi: 10.18632/aging.100140
Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517–31.
pubmed: 18568040
pmcid: 3915522
doi: 10.1038/nrm2438
Letourneux C, Rocher G, Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 2006;25:727–38.
pubmed: 16456541
pmcid: 1383561
doi: 10.1038/sj.emboj.7600980
Lin SS, Bassik MC, Suh H, Nishino M, Arroyo JD, Hahn WC, et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum*. J Biol Chem. 2006;281:23003–12.
pubmed: 16717086
doi: 10.1074/jbc.M602648200
Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, et al. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res. 2014;12:924–39.
pubmed: 24667985
pmcid: 4116560
doi: 10.1158/1541-7786.MCR-13-0542
Janghorban M, Langer EM, Wang X, Zachman D, Daniel CJ, Hooper J, et al. The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model. PLoS ONE. 2017;12:e0188910.
pubmed: 29190822
pmcid: 5708644
doi: 10.1371/journal.pone.0188910
Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, et al. Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep. 2015;5:13099.
pubmed: 26278961
pmcid: 4642524
doi: 10.1038/srep13099
Chang W-H, Liu Y, Hammes EA, Bryant KL, Cerione RA, Antonyak MA. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin. J Biol Chem. 2023;299:102842.
pubmed: 36581205
doi: 10.1016/j.jbc.2022.102842
Wu Y, Gu T-T, Zheng P-S. CIP2A cooperates with H-Ras to promote epithelial–mesenchymal transition in cervical-cancer progression. Cancer Lett. 2015;356:646–55.
pubmed: 25458953
doi: 10.1016/j.canlet.2014.10.013
Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56α associates with c-Myc and negatively regulates c-Myc accumulation. Mol Cell Biol. 2006;26:2832–44.
pubmed: 16537924
pmcid: 1430332
doi: 10.1128/MCB.26.7.2832-2844.2006
Farrell AS, Sears RC. MYC Degradation. CSH Perspect Med. 2014;4:a014365.
Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, et al. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO Rep. 2017;18:437–50.
pubmed: 28174209
pmcid: 5331240
doi: 10.15252/embr.201642788
Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999;3:169–79.
pubmed: 10078200
doi: 10.1016/S1097-2765(00)80308-1
Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of β-Catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283:2089–91.
pubmed: 10092233
doi: 10.1126/science.283.5410.2089
Martinez AKF, Storz P. Mimicking and manipulating pancreatic acinar-to-ductal metaplasia in 3-dimensional cell culture. J Vis Exp. (144), e59096, https://doi.org/10.3791/59096 (2019).
Shi G, DiRenzo D, Qu C, Barney D, Miley D, Konieczny SF. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene. 2013;32:1950–8.
pubmed: 22665051
doi: 10.1038/onc.2012.210
Tinsley SL, Allen-Petersen BL. PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen. NAR Cancer. 2022;4:zcac002-.
pubmed: 35118387
pmcid: 8807117
doi: 10.1093/narcan/zcac002
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al. Repression of the Type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 2020;10:872–87.
pubmed: 32200350
pmcid: 7611248
doi: 10.1158/2159-8290.CD-19-0620
Aakula A, Sharma M, Tabaro F, Nätkin R, Kamila J, Honkanen H, et al. RAS and PP2A activities converge on epigenetic gene regulation. Life Sci Alliance. 2023;6:e202301928.
pubmed: 36858798
pmcid: 9979842
doi: 10.26508/lsa.202301928
Vogt M, Stankovic ND, Garcia YC, Hofstetter J, Schneider K, Kuybu F. et al. Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. Gut. 2024;73:1509–1528.
pubmed: 38821858
doi: 10.1136/gutjnl-2023-331519
Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18.
Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z. Selective PP2A enhancement through biased heterotrimer stabilization. Cell. 2020;181:688–701.
pubmed: 32315618
pmcid: 7243596
doi: 10.1016/j.cell.2020.03.038
Kemp SB, Cheng N, Markosyan N, Sor R, Kim I-K, Hallin J, et al. Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2022;13:298–311.
pmcid: 9900321
doi: 10.1158/2159-8290.CD-22-1066
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.
pubmed: 15894267
doi: 10.1016/j.ccr.2005.04.023
Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022;3:272–86.
pubmed: 35352061
doi: 10.1038/s43018-022-00349-2
Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S. et al. Myc instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 2020;10(4):588–607.
pubmed: 31941709
doi: 10.1158/2159-8290.CD-19-0435
Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE. 2011;6:e17979.
pubmed: 21445343
pmcid: 3062549
doi: 10.1371/journal.pone.0017979
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14.
pubmed: 11018017
pmcid: 316970
doi: 10.1101/gad.836800
Pavic K, Gupta N, Omella JD, Derua R, Aakula A, Huhtaniemi R, et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nat Commun. 2023;14:1143.
pubmed: 36854761
pmcid: 9974998
doi: 10.1038/s41467-023-36693-9
Cristóbal I, Torrejón B, Madoz-Gúrpide J, Rojo F, García-Foncillas J. PP2A plays a key role in inflammation and cancer through tristetraprolin activation. Ann Rheum Dis. 2017;76:e11.
pubmed: 27811146
doi: 10.1136/annrheumdis-2016-210684
McHugh WM, Russell WW, Fleszar AJ, Rodenhouse PE, Rietberg SP, Sun L, et al. Protein phosphatase 2A activation attenuates inflammation in murine models of acute lung injury. Am J Physiol-Lung Cell Mol Physiol. 2016;311:L903–12.
pubmed: 27638902
pmcid: 5130532
doi: 10.1152/ajplung.00007.2016
Clark AR, Ohlmeyer M. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. Pharmacol Ther. 2019;201:181–201.
pubmed: 31158394
pmcid: 6700395
doi: 10.1016/j.pharmthera.2019.05.016
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Investig. 2017;127:2081–90.
pubmed: 28504649
pmcid: 5451217
doi: 10.1172/JCI89548
Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, et al. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma. JCI Insight. 2019;4:e125693.
pubmed: 30830869
pmcid: 6478418
doi: 10.1172/jci.insight.125693
Kauko O, O’Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med. 2018;10:eaaq1093.
pubmed: 30021885
pmcid: 8335581
doi: 10.1126/scitranslmed.aaq1093
McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, et al. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018;78:2065–80.
pubmed: 29358171
pmcid: 5899650
doi: 10.1158/0008-5472.CAN-17-0123
Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, et al. Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death. Mol Cancer Ther. 2023;22:599–615.
pubmed: 36788429
pmcid: 10157366
doi: 10.1158/1535-7163.MCT-21-0880
Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, et al. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Res. 2018;79:209–19.
pubmed: 30389701
pmcid: 6318036
doi: 10.1158/0008-5472.CAN-18-0717
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. N Engl J Med. 2022;388:33–43.
pubmed: 36546651
pmcid: 10506456
doi: 10.1056/NEJMoa2208470
Zhang J, Darman L, Hassan MS, Holzen UV, Awasthi N. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Oncol Rep. 2023;50:206.
pubmed: 37800636
pmcid: 10570661
doi: 10.3892/or.2023.8643
Federico AD, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, et al. Resistance to KRAS G12C inhibition in non-small cell lung cancer. Curr Oncol Rep. 2023;25:1017–29.
pubmed: 37378881
doi: 10.1007/s11912-023-01436-y
Aiello NM, Rhim AD, Stanger BZ. Orthotopic injection of pancreatic cancer cells. Cold Spring Harb Protoc. 2016;2016:pdb.prot078360.
pubmed: 26729902
doi: 10.1101/pdb.prot078360
Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884–90.
pubmed: 30423086
pmcid: 6129281
doi: 10.1093/bioinformatics/bty560
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Liao Y, Smyth GK, Shi W. The subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108–e108.
pubmed: 23558742
pmcid: 3664803
doi: 10.1093/nar/gkt214
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetJ. 2011;17:10–2.
doi: 10.14806/ej.17.1.200
Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.
pubmed: 19451168
pmcid: 2705234
doi: 10.1093/bioinformatics/btp324
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160–5.
pubmed: 27079975
pmcid: 4987876
doi: 10.1093/nar/gkw257
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.
pubmed: 20110278
pmcid: 2832824
doi: 10.1093/bioinformatics/btq033
Yu G, Wang L-G, He Q-Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015;31:2382–3.
pubmed: 25765347
doi: 10.1093/bioinformatics/btv145
Heberle H, Meirelles GV, Silva FR, da, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinform. 2015;16:169.
doi: 10.1186/s12859-015-0611-3
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90–7.
pubmed: 27141961
pmcid: 4987924
doi: 10.1093/nar/gkw377
Daniel CJ, Sun X-X, Chen Y, Zhang X, Dai M-S, Sears RC. The Myc gene, methods and protocols. Methods Mol Biol. 2021;2318:69–85.
pubmed: 34019287
doi: 10.1007/978-1-0716-1476-1_5